FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMN
The decision is based on results from the Phase III MAJESTY study.
Drug Development
Innovent licenses IBI355 rights to Spero for up to $1.1bn
Novartis and Chai Discovery collaborate on antibody identification
Cellares and Sonoma partner to automate cell therapy manufacturing
Takeda and Indonesia partner on plasma-derived therapies
FDA approves MSD’s Keytruda combinations for MIBC
Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar
Apertura and NIH institutes to test gene therapy for NPC1
